Fresenius

Amikacin Sulfate Injection, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

After nine months of construction, a new central sterilization unit has been opened at HELIOS Hospital Dr. Horst Schmidt Kliniken in Wiesbaden, Germany. Up to 75,000 medical instruments will be cleaned and sterilized annually in the unit, for use in five HELIOS hospitals. The total investment was about €4 million.

April 04

April 04, 2016
Zurich, Switzerland

Roadshow Zurich

Presentation Import (ICS)

The Supervisory Board of Fresenius Medical Care AG & Co. KGaA has decided in its meeting on March 9, 2016, to propose to the Annual General Meeting on May 12, 2016 the following candidates for regular election to the Supervisory Board:

  • Dr. Gerd Krick, former Chairman of the Management Board of Fresenius AG, Chairman of the Supervisory Board since 1998
  • Dr. Dieter Schenk, attorney and tax advisor, partner of Noerr LLP, Vice Chairman of the Supervisory Board since 1996
  • Rolf A. Classon, Chairman of the Board of Directors of Hill-Rom Corp. (formerly Hillenbrand Industries, Inc.), member of the Supervisory Board since 2011
  • William P. Johnston, former Chairman of the Board of Directors of the Renal Care Group, Inc., member of the Supervisory Board since 2006
  • Deborah Doyle McWhinney, former Chief Executive Officer and Chief Operating Officer of Citi Enterprise Payments (Citigroup, Inc.)
  • Pascale Witz, Executive Vice President, Global Diabetes & Cardiovascular, Sanofi S.A.

In case of the election by the Annual General Meeting, two new members, Deborah Doyle McWhinney and Pascale Witz, will join the Supervisory Board. Dr. Walter L. Weisman, member of the Supervisory Board since 1996, as well as Prof. Dr. Bernd Fahrholz, member of the Supervisory Board since 1998, will leave the Supervisory Board following the Annual General Meeting on May 12, 2016.

The Supervisory Board proposes the election of the candidates to the Supervisory Board for a 5 year term until the conclusion of the Annual General Meeting which resolves on the discharge for fiscal year 2020.

It is intended to propose the election of Dr. Gerd Krick as Chairman of the Supervisory Board in case of his reelection as a member of the Supervisory Board.

Dr. Gerd Krick, Dr. Dieter Schenk, Rolf A. Classon and William P. Johnston as well as Dr. Ulf M. Schneider shall continue to be members of the Supervisory Board of Fresenius Medical Care Management AG. Stephan Sturm, Chief Financial Officer of Fresenius, shall be elected as a new member of the Supervisory Board. Dr. Walter L. Weisman will leave the Supervisory Board effective on May 12, 2016.

Fresenius Medical Care Management AG is the General Partner of Fresenius Medical Care AG & Co. KGaA, which acts on its own responsibility, manages the Company and conducts the Company's business. The Supervisory Board of Fresenius Medical Care Management AG appoints the members of the Management Board of Fresenius Medical Care Management AG.

The invitation and detailed agenda for the Annual General Meeting of Fresenius Medical Care AG & Co. KGaA on May 12, 2016, are expected to be published on March 31, 2016.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

 

At its meeting today, the Supervisory Board of Fresenius SE & Co. KGaA nominated the following candidates for election to the Supervisory Board by the Annual General Meeting on May 13, 2016:

  • Prof. Dr. med. D. Michael Albrecht, Medical Director and Spokesman of the Management Board of the Universitätsklinikum Carl Gustav Carus Dresden; member of the Supervisory Board since 2011
  • Michael Diekmann, former Chief Executive Officer of Allianz SE; member of the Supervisory Board since 2015
  • Dr. Gerd Krick, former Chief Executive Officer of Fresenius AG; member of the Supervisory Board since 2003
  • Prof. Dr. med. Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President, Head of Development and Medical Patient Value Practices at UCB S.A.
  • Klaus-Peter Müller, Chairman of the Supervisory Board of Commerzbank AG; member of the Supervisory Board since 2008
  • Hauke Stars, Member of the Management Board of Deutsche Börse AG

If elected by the Annual General Meeting, Prof. Dr. med. Iris Löw-Friedrich und Ms. Hauke Stars will join the Supervisory Board as new shareholder representatives. Prof. Dr. Roland Berger, a member since 2008, and Gerhard Roggemann, a member from 1998 to 2004 and again since 2011, will leave the Supervisory Board at the close of the Annual General Meeting.

All candidates are nominated for a five-year term, ending with the close of the 2021 Annual General Meeting. If re-elected to the Supervisory Board, Dr. Gerd Krick will be proposed for election as Chairman.

The Supervisory Board of Fresenius SE & Co. KGaA consists of 12 members. The six employee representatives are elected by the European works council.

Dr. Gerd Krick, Michael Diekmann and Klaus-Peter Müller, as well as Dr. Dieter Schenk, a lawyer and tax consultant, and Dr. Karl Schneider, former Spokesman of the Management Board of Südzucker AG, are nominated for re-election to the Supervisory Board of Fresenius Management SE. Effective on May 13, 2016, Prof. Dr. Roland Berger will leave the Supervisory Board of Fresenius Management SE. Dr. Kurt Bock, Chief Executive Officer of BASF SE, is nominated to join the Supervisory Board of Fresenius Management SE.

As the general partner, Fresenius Management SE manages Fresenius SE & Co. KGaA. The Supervisory Board of Fresenius Management SE, which consists of six members and is not subject to employee co-determination, appoints the Management Board of Fresenius Management SE.

The invitation and complete agenda for the Annual General Meeting of Fresenius SE & Co. KGaA, to be held on May 13, 2016, will be published on March 31, 2016.

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

At its meeting today, the Supervisory Board of Fresenius SE & Co. KGaA nominated the following candidates for election to the Supervisory Board by the Annual General Meeting on May 13, 2016:

  • Prof. Dr. med. D. Michael Albrecht, Medical Director and Spokesman of the Management Board of the Universitätsklinikum Carl Gustav Carus Dresden; member of the Supervisory Board since 2011
  • Michael Diekmann, former Chief Executive Officer of Allianz SE; member of the Supervisory Board since 2015
  • Dr. Gerd Krick, former Chief Executive Officer of Fresenius AG; member of the Supervisory Board since 2003
  • Prof. Dr. med. Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President, Head of Development and Medical Patient Value Practices at UCB S.A.
  • Klaus-Peter Müller, Chairman of the Supervisory Board of Commerzbank AG; member of the Supervisory Board since 2008
  • Hauke Stars, Member of the Management Board of Deutsche Börse AG

If elected by the Annual General Meeting, Prof. Dr. med. Iris Löw-Friedrich und Ms. Hauke Stars will join the Supervisory Board as new shareholder representatives. Prof. Dr. Roland Berger, a member since 2008, and Gerhard Roggemann, a member from 1998 to 2004 and again since 2011, will leave the Supervisory Board at the close of the Annual General Meeting.

All candidates are nominated for a five-year term, ending with the close of the 2021 Annual General Meeting. If re-elected to the Supervisory Board, Dr. Gerd Krick will be proposed for election as Chairman.

The Supervisory Board of Fresenius SE & Co. KGaA consists of 12 members. The six employee representatives are elected by the European works council.

Dr. Gerd Krick, Michael Diekmann and Klaus-Peter Müller, as well as Dr. Dieter Schenk, a lawyer and tax consultant, and Dr. Karl Schneider, former Spokesman of the Management Board of Südzucker AG, are nominated for re-election to the Supervisory Board of Fresenius Management SE. Effective on May 13, 2016, Prof. Dr. Roland Berger will leave the Supervisory Board of Fresenius Management SE. Dr. Kurt Bock, Chief Executive Officer of BASF SE, is nominated to join the Supervisory Board of Fresenius Management SE.

As the general partner, Fresenius Management SE manages Fresenius SE & Co. KGaA. The Supervisory Board of Fresenius Management SE, which consists of six members and is not subject to employee co-determination, appoints the Management Board of Fresenius Management SE.

The invitation and complete agenda for the Annual General Meeting of Fresenius SE & Co. KGaA, to be held on May 13, 2016, will be published on March 31, 2016.

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

March 17

March 17, 2016
Bad Homburg, Germany

Annual Report 2015 (U.S. GAAP)

and Consolidated Financial Statements and Management Report (IFRS)

IFRS Report U.S. GAAP Report Import (ICS)
Subscribe to